Date of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral
Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for the treatment of R/R MCL. Similarly, venetoclax, an oral BCL2 inhibitor, has gained approval in multiple countries for managing chronic lymphocytic leukemia and untreated acute myeloid leukemia. The SYMPATICO study, a multinational, double-blind trial, recruited patients with relapsed/refractory MCL who had undergone 1 to 5 prior therapies for the condition. The findings presented at the ASH 2023 conference demonstrated that, the median assessed PFS was 31.9 months in the...
